Gain-of-function RET pathogenic variants are potent oncogenic drivers and are associated with multiple endocrine neoplasia type 2 (MEN2) as well as sporadic medullary thyroid carcinoma (MTC). This evidence concerns the gene RET and medullary thyroid gland carcinoma.